Intravenous immunoglobulin (IVIG) is recommended by both European and Spanish clinical guidelines for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and myasthenia gravis (MG).
Subcutaneous immunoglobulin (SCIG) is gaining interest due to home self-administration, a favorable safety profile, and potential cost savings. However, real-world evidence on healthcare resource utilization and associated costs remains limited.
This study aims to compare healthcare resource consumption and total treatment costs of SCIG versus IVIG in patients with CIDP, MMN and MG treated at two tertiary hospitals in Spain.